Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAN2401 placebo-controlled phase 3 study in early Alzheimer's disease with open-label extension
CTR20200005Phase 3Active
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of lecanemab in Alzheimer's disease (AD), mild cognitive impairment due to Alzheimer's disease, sponsored by Eisai Co., Ltd.. Started Nov 2020; status: active.
02
Drugs
lecanemab
03
Conditions
Alzheimer's disease (AD)mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on CTR20200005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200005.